6-Fluoro-2,2-dimethyl-chroman-4-ol | 132686-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-Fluoro-2,2-dimethyl-chroman-4-ol
• 英文别名: 6-Fluoro-2,2-dimethylchroman-4-ol；6-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-ol
• CAS: 132686-72-7
• 化学式: C₁₁H₁₃FO₂
• 分子量: 196.221
• InChiKey: BEZSNFOXBWMXRK-UHFFFAOYSA-N

物化性质

• 沸点：
  265.1±40.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Fluoro-2,2-dimethyl-chroman-4-ol 在 盐酸 、 硫酸 作用下， 生成 4-amino-3,4-dihydro-2,2-dimethyl-6-fluoro-(2H)-1-benzopyran
  参考文献：
  名称：

  4,6-Disubstituted 2,2-Dimethylchromans Structurally Related to the K_ATP Channel Opener Cromakalim: Design, Synthesis, and Effect on Insulin Release and Vascular Tone

  摘要：

  Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic beta-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a K-ATP channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.

  DOI：

  10.1021/jm040789e
• 作为产物：
  描述：

  4-氟苯基醋酸酯 在 四氢吡咯 、 sodium tetrahydroborate 、 三氯化铝 作用下， 以 甲醇 为溶剂， 生成 6-Fluoro-2,2-dimethyl-chroman-4-ol
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of K<SUB>ATP</SUB>-channel Openers Related to Cromakalim: Introduction of Arylsulphonylurea Moieties

  摘要：

  DOI：

  10.1211/146080899128734587

文献信息

• TRPV1 ANTAGONISTS
  申请人：Gomtsyan Arthur R.

  公开号：US20100120846A1

  公开（公告）日：2010-05-13

  Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , R 4 , and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了式(I)的化合物，或其药学上可接受的盐、溶剂、前药盐、前药的盐或其组合物，其中R1、R2、R3、R4和m在规范中被定义。还揭示了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和病症的方法。
• SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND
  申请人：Schroeder Rudolf

  公开号：US20090143423A1

  公开（公告）日：2009-06-04

  A solid dispersion product comprising at least one N-aryl urea-based pharmaceutically active agent or an agent of related structural type is obtained by a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix-forming agent, at least one pharmaceutically acceptable surfactant and at least one solvent, and b) removing the solvent(s) from the liquid mixture to obtain the solid dispersion product.

  通过a)制备含有至少一种N-芳基脲基药物活性剂或相关结构类型的药剂学活性剂的固体分散产品，包括制备液体混合物，其中包含至少一种活性剂、至少一种药学上可接受的基质形成剂、至少一种药学上可接受的表面活性剂和至少一种溶剂，然后b)从液体混合物中去除溶剂，以获得固体分散物。
• Synthesis and Activity of Novel and Selective I_Ks-Channel Blockers
  作者：Uwe Gerlach、Joachim Brendel、Hans-Jochen Lang、Erich F. Paulus、Klaus Weidmann、Andrea Brüggemann、Andreas E. Busch、Hartmut Suessbrich、Markus Bleich、Rainer Greger

  DOI：10.1021/jm0109255

  日期：2001.11.1

  Since the discovery of the I-Ks-potassium channel as the slowly activating component of the delayed rectifier current (I-k) in cardiac tissue, the search for blockers of this current has been intense. During the screening of K-ATP-channel openers of the chromanol type we found that chromanol 293B was able to block I-Ks. Chromanol 293B is a sulfonamide analogue of the K-ATP-channel openers but had no activity on this target. Experiments were initiated to improve the activity and properties based on this lead compound. As a screening model we used Xenopus oocytes injected with human minK (KCNE1). Variations of the aromatic substituent and the sulfonamide group were prepared, and their activity was evaluated. We found that the greatest influence on activity was found in the aromatic substituents. The most active compounds were alkoxy substituted. We chose HMR1556 ((3R, 4S)-(+)-N-[-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)chroman-4-yl]-N-methyl-ethanesulfonamide) 10a for development as an antiarrhythmic drug. The absolute configuration, resulting from an X-ray single-crystal structure analysis, was determined.
• US8604053B2
  申请人：——

  公开号：US8604053B2

  公开（公告）日：2013-12-10
• US8609692B2
  申请人：——

  公开号：US8609692B2

  公开（公告）日：2013-12-17